Quest Diagnostics Inc (DGX) EVP J. E. Davis Sells 63,880 Shares
Quest Diagnostics Inc (NYSE:DGX) EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $98.68, for a total value of $6,303,678.40. Following the completion of the transaction, the executive vice president now directly owns 101,423 shares in the company, valued at approximately $10,008,421.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Quest Diagnostics Inc (NYSE DGX) traded down $0.17 on Friday, hitting $99.08. The stock had a trading volume of 933,400 shares, compared to its average volume of 887,767. Quest Diagnostics Inc has a one year low of $90.10 and a one year high of $112.96. The company has a market cap of $13,550.00, a PE ratio of 20.64, a price-to-earnings-growth ratio of 2.03 and a beta of 0.60. The company has a quick ratio of 1.37, a current ratio of 1.47 and a debt-to-equity ratio of 0.78.
Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The business had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.92 billion. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. Quest Diagnostics’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period last year, the company earned $1.37 EPS. research analysts anticipate that Quest Diagnostics Inc will post 5.65 earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC grew its holdings in Quest Diagnostics by 5.7% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 416,567 shares of the medical research company’s stock worth $39,007,000 after acquiring an additional 22,399 shares during the period. AXA grew its holdings in Quest Diagnostics by 38.7% during the 3rd quarter. AXA now owns 80,875 shares of the medical research company’s stock worth $7,573,000 after acquiring an additional 22,575 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in Quest Diagnostics during the 3rd quarter worth about $446,000. GSA Capital Partners LLP grew its holdings in Quest Diagnostics by 1,376.0% during the 3rd quarter. GSA Capital Partners LLP now owns 31,556 shares of the medical research company’s stock worth $2,955,000 after acquiring an additional 29,418 shares during the period. Finally, Coastline Trust Co grew its holdings in Quest Diagnostics by 5.6% during the 3rd quarter. Coastline Trust Co now owns 15,725 shares of the medical research company’s stock worth $1,473,000 after acquiring an additional 830 shares during the period. 88.84% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have recently commented on DGX shares. Raymond James Financial reaffirmed a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, September 25th. Goldman Sachs Group downgraded Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and decreased their target price for the company from $121.00 to $113.00 in a research report on Tuesday, October 10th. Canaccord Genuity reaffirmed a “buy” rating and issued a $118.00 target price on shares of Quest Diagnostics in a research report on Wednesday, September 13th. Zacks Investment Research downgraded Quest Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, October 27th. Finally, Citigroup reduced their price target on Quest Diagnostics from $110.00 to $98.00 and set a “neutral” rating on the stock in a research report on Friday, October 20th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $106.20.
ILLEGAL ACTIVITY NOTICE: “Quest Diagnostics Inc (DGX) EVP J. E. Davis Sells 63,880 Shares” was reported by Marea Informative and is the property of of Marea Informative. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.mareainformativa.com/2018/01/05/quest-diagnostics-inc-dgx-evp-j-e-davis-sells-63880-shares.html.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.